Trial Profile
An open label study to evaluate the safety, and effect on treatment response, of MabThera in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response or intolerance to one or more anti-TNF agents.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 21 May 2012 Actual end date Apr 2010 added as reported by ClinicalTrials.gov.
- 18 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2009 Planned end date changed from 1 Nov 2008 to 1 Jul 2010, according to clinicaltrials.gov.